Immediate postoperative adjuvant hormonal treatment in high risk localised or locally advanced prostate cancer patients.
Study identifier:NIS-OCN-DUM-2009/2
ClinicalTrials.gov identifier:NCT01123434
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Non-interventional Study of immediate postoperative adjuvant hormonal treatment in high risk localised or locally advanced Chinese prostate cancer patients.
Medical condition
2 years PSA recurrence rate
Phase
-
Healthy volunteers
No
Study drug
-
Sex
Male
Actual Enrollment
200
Study type
Observational
Age
18 Years +
Date
Study Start Date: 01 Apr 2010
Primary Completion Date: 01 Aug 2014
Study Completion Date: 01 Aug 2014
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 May 2016 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| 1 Localised with one of any high recurrence risk factors, or locally advanced Chinese prostate cancer patients confirmed histologically through radical prostatectomy either with laparoscopy or laparotomy within 1 month after surgery. Before the patient recruitment, the investigator has decided to prescribe immediate postoperative adjuvant hormonal treatment to the patient according to the Chinese routine practice. | - |
Contacts
Investigators
Principal Investigator
Karen Atkin
AstraZeneca
